Small cell lung cancer

George R. Simon, Henry Wagner Jr.

Research output: Contribution to journalReview article

204 Citations (Scopus)

Abstract

Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.

Original languageEnglish (US)
Pages (from-to)259S-271S
JournalChest
Volume123
Issue number1 SUPPL.
DOIs
StatePublished - Jan 1 2003

Fingerprint

Small Cell Lung Carcinoma
Cranial Irradiation
Drug Therapy
Survival
Bone Marrow Transplantation
Positron-Emission Tomography
Abdomen
Lung Neoplasms
Radiotherapy
Thorax
Therapeutics
Magnetic Resonance Imaging
Guidelines
Bone and Bones
Brain

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Simon, George R. ; Wagner Jr., Henry. / Small cell lung cancer. In: Chest. 2003 ; Vol. 123, No. 1 SUPPL. pp. 259S-271S.
@article{b592bbfdc9da480ebef0b37c0540fe8a,
title = "Small cell lung cancer",
abstract = "Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20{\%} of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70{\%} and a complete response rate of 20 to 30{\%}, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.",
author = "Simon, {George R.} and {Wagner Jr.}, Henry",
year = "2003",
month = "1",
day = "1",
doi = "10.1378/chest.123.1_suppl.259S",
language = "English (US)",
volume = "123",
pages = "259S--271S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1 SUPPL.",

}

Simon, GR & Wagner Jr., H 2003, 'Small cell lung cancer', Chest, vol. 123, no. 1 SUPPL., pp. 259S-271S. https://doi.org/10.1378/chest.123.1_suppl.259S

Small cell lung cancer. / Simon, George R.; Wagner Jr., Henry.

In: Chest, Vol. 123, No. 1 SUPPL., 01.01.2003, p. 259S-271S.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Small cell lung cancer

AU - Simon, George R.

AU - Wagner Jr., Henry

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.

AB - Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain. The role for positron emission tomography scanning in the staging of SCLC has yet to be defined. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC. Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.

UR - http://www.scopus.com/inward/record.url?scp=0037247903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037247903&partnerID=8YFLogxK

U2 - 10.1378/chest.123.1_suppl.259S

DO - 10.1378/chest.123.1_suppl.259S

M3 - Review article

C2 - 12527584

AN - SCOPUS:0037247903

VL - 123

SP - 259S-271S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1 SUPPL.

ER -